Identification of novel candidate genes for Ascochyta blight resistance in chickpea.

Ascochyta blight, caused by the necrotrophic fungus Ascochyta rabiei, is a major threat to chickpea production worldwide. Resistance genes with broad-spectrum protection against virulent A. rabiei strains are required to secure chickpea yield in the US Northern Great Plains.

Clinical and molecular genetic characteristics of patients with hereditary hypophosphatemia.

Background: Hereditary hypophosphatemia (HH), is a rare condition related to decreased renal tubular phosphate reabsorption. Although X-linked hypophosphatemia or PHEX gene variant is the most frequent cause of HH, recent advances in next-generation sequencing (NGS) techniques enable the identification of genetic etiologies as a whole.

Objective: To identify genetic causes of HH using various genetic testing methods and to compare clinical features between FGF23-dependent and FGF23-independent HH groups.

Depression among keratoconus patients: a systematic review and meta-analysis.

Background: Keratoconus (KC) is a chronic corneal disease that typically presents in early adulthood, and may potentially result in poor mental health in affected individuals. The evidence regarding the association of depression with KC is controversial. Hence, we investigated the association between depression and KC via a systematic review and meta-analysis.

A systematic review of the potential treatment effects of topical epidermal growth factor for ocular surface disorders.

Purpose: This systematic review, evaluated the role of epidermal growth factor (EGF) in corneal wound healing and the pathogenesis of ocular surface disorders (OSDs).

Methods: The clinical and experimental application of topical EGF therapy for OSDs was reviewed. This systematic research assessed articles published on PubMed/MEDLINE from 2000 to 2023 and summarized and discussed the findings of 38 experimental and 10 clinical studies.

A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.

Purpose: Early in the course of the SARS-CoV-2 pandemic it was hypothesised that host genetics played a role in the pathophysiology of COVID-19 including a suggestion that the CCR5-Δ32 mutation may be protective in SARS-CoV-2 infection. Leronlimab is an investigational CCR5-specific humanized IgG4 monoclonal antibody currently in development for HIV-1 infection. We aimed to explore the impact of leronlimab on the severity of disease symptoms among participants with mild-to-moderate COVID-19.